Physician
Advanced Diagnostic Imaging, PC
Advanced Diagnostic Imaging, PC was paid $29.82M by Medicaid between Jan 2018 and Dec 2024, across 320 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoADVANCED DIAGNOSTIC IMAGING, PC
GOODLETTSVILLE, TN 37072
GOODLETTSVILLE, TN 37072
33aNPI1093741464assigned 06/25/2006
33bProvider typeDermatology Physician
28Total paid$29.82M
24GClaims1,370,852
24DCodes billed320
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Dermatology Physician providers in Tennessee
Rank by total paid#1 of 42
Median peer was paid$55K
This provider vs. median539×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 58,607 | $1.41M | |
| 2019 | 92,289 | $2.13M | |
| 2020 | 177,740 | $3.95M | |
| 2021 | 276,955 | $6.20M | |
| 2022 | 280,459 | $6.11M | |
| 2023 | 280,512 | $5.48M | |
| 2024incomplete | 204,290 | $4.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 449,610 | 342,770 | $11.12M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 172,703 | 134,194 | $3.83M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.0% | 32,380 | 26,628 | $1.80M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.5% | 24,227 | 20,404 | $1.04M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 56,461 | 48,900 | $705K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | 2.3% | 80,287 | 30,403 | $686K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 2.1% | 4,485 | 3,676 | $638K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.1% | 10,388 | 3,916 | $617K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 23,400 | 6,817 | $566K |
| 64635 | 1.7% | 3,790 | 2,665 | $503K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.4% | 13,381 | 10,252 | $427K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 1.4% | 19,173 | 4,806 | $423K |
308 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.0% | 7,019 | $307K |
| 20611 | 1.0% | 10,648 | $300K | |
| 64493 | <1% | 5,428 | $261K | |
| 62323 | <1% | 3,648 | $248K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,586 | $246K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,557 | $226K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 19,265 | $198K |
| 99349 | <1% | 10,881 | $192K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 912 | $184K |
| 76830 | Ultrasound, transvaginal | <1% | 2,940 | $180K |
| 64636 | <1% | 3,493 | $172K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,003 | $168K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,719 | $164K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,757 | $162K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,374 | $158K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 823 | $131K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,640 | $123K |
| 95117 | <1% | 11,709 | $117K | |
| 20610 | <1% | 5,294 | $101K | |
| 64494 | <1% | 4,641 | $99K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,100 | $92K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,419 | $89K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,612 | $89K |
| 73630 | <1% | 8,020 | $84K | |
| 76801 | <1% | 1,488 | $84K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 603 | $83K |
| 99310 | Prolong nursin fac eval 15m | <1% | 8,026 | $83K |
| 99223 | Prolong inpt eval add15 m | <1% | 2,270 | $80K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 3,438 | $79K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,045 | $79K |
| 59025 | Fetal non-stress test | <1% | 2,532 | $77K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,919 | $77K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,873 | $76K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 537 | $72K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,609 | $71K |
| 01992 | <1% | 1,227 | $66K | |
| 17110 | <1% | 1,337 | $57K | |
| 11721 | <1% | 8,876 | $57K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,210 | $52K |
| 99350 | Prolong home eval add 15m | <1% | 1,792 | $52K |
| 88313 | <1% | 2,493 | $49K | |
| 92567 | <1% | 4,561 | $49K | |
| 59510 | <1% | 47 | $48K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,146 | $46K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 40 | $46K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,931 | $45K |
| 92587 | <1% | 1,357 | $44K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,243 | $44K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 687 | $43K |
| 88312 | <1% | 1,405 | $42K | |
| 76942 | <1% | 1,160 | $42K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,407 | $41K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 5,882 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,805 | $40K |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | <1% | 291 | $39K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 8,483 | $38K |
| 64483 | <1% | 456 | $36K | |
| 81025 | <1% | 8,701 | $35K | |
| 95806 | <1% | 464 | $34K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,045 | $34K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 2,726 | $33K |
| 99356 | <1% | 3,674 | $33K | |
| 88342 | <1% | 1,048 | $33K | |
| 94729 | <1% | 2,485 | $32K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,613 | $32K |
| 93970 | <1% | 320 | $31K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 744 | $31K |
| 95886 | <1% | 514 | $30K | |
| 62321 | <1% | 521 | $30K | |
| 97161 | <1% | 916 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 891 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,032 | $26K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 458 | $26K |
| 94010 | <1% | 2,480 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,500 | $24K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,563 | $24K |
| 93971 | <1% | 385 | $23K | |
| 94060 | <1% | 1,610 | $23K | |
| 99490 | Ccm add 20min | <1% | 8,666 | $22K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,933 | $21K |
| 93000 | <1% | 3,339 | $19K | |
| 11100 | <1% | 494 | $18K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 599 | $18K |
| 01922 | <1% | 250 | $17K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 206 | $17K |
| 72100 | <1% | 1,429 | $17K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,257 | $17K |
| 97016 | <1% | 4,051 | $17K | |
| 95115 | <1% | 2,246 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,270 | $17K |
| 94727 | <1% | 1,515 | $15K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 892 | $15K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,580 | $15K |
| 99348 | <1% | 1,055 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,217 | $14K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 291 | $13K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 201 | $13K |
| 72110 | <1% | 1,201 | $13K | |
| 99439 | <1% | 3,853 | $12K | |
| 92557 | <1% | 598 | $12K | |
| 73564 | <1% | 897 | $12K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 260 | $12K |
| 99442 | <1% | 823 | $11K | |
| 46600 | <1% | 297 | $11K | |
| 99354 | <1% | 877 | $11K | |
| 90674 | <1% | 475 | $10K | |
| 59514 | <1% | 19 | $10K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,392 | $10K |
| 95911 | <1% | 97 | $10K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 15 | $10K |
| 80305 | <1% | 2,569 | $10K | |
| 81003 | <1% | 10,011 | $10K | |
| 99454 | <1% | 4,007 | $10K | |
| 73562 | <1% | 945 | $9K | |
| 99457 | <1% | 3,766 | $9K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 317 | $9K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 137 | $8K |
| 99406 | <1% | 1,695 | $8K | |
| 76818 | <1% | 105 | $8K | |
| L3984 | Upper extremity fracture orthosis, wrist, prefabricated, includes fitting and adjustment | <1% | 67 | $7K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 66 | $7K |
| 96127 | <1% | 2,126 | $7K | |
| 11102 | <1% | 167 | $7K | |
| 99205 | Prolong outpt/office vis | <1% | 67 | $7K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 203 | $7K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 317 | $7K |
| 20553 | <1% | 526 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,403 | $6K |
| 99441 | <1% | 667 | $6K | |
| 99306 | Prolong nursin fac eval 15m | <1% | 405 | $6K |
| 51798 | <1% | 854 | $6K | |
| 90715 | <1% | 125 | $5K | |
| 64490 | <1% | 87 | $5K | |
| 99307 | <1% | 637 | $5K | |
| 99385 | <1% | 81 | $5K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 77 | $5K |
| 99221 | <1% | 157 | $5K | |
| 99443 | <1% | 387 | $5K | |
| 99497 | <1% | 321 | $4K | |
| L1902 | Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf | <1% | 127 | $4K |
| 93304 | <1% | 50 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 32 | $4K |
| 93325 | <1% | 82 | $4K | |
| 59425 | <1% | 13 | $4K | |
| 59426 | <1% | 13 | $4K | |
| 72170 | <1% | 604 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,354 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 111 | $4K |
| 20552 | <1% | 172 | $4K | |
| 0500F | <1% | 440 | $4K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 945 | $4K |
| A9505 | Thallium tl-201 thallous chloride, diagnostic, per millicurie | <1% | 193 | $4K |
| 95251 | <1% | 448 | $4K | |
| L3000 | Foot, insert, removable, molded to patient model, 'ucb' type, berkeley shell, each | <1% | 28 | $4K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 277 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 129 | $3K |
| 93015 | <1% | 275 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 255 | $3K |
| 90682 | <1% | 58 | $3K | |
| 92552 | <1% | 354 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,473 | $3K |
| 81002 | <1% | 1,645 | $3K | |
| G0317 | Prolonged nursing facility evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99306, 99310 for nursing facility evaluation and management services). (do not report g0317 on the same date of service as other prolonged services for evaluation and management 99358, 99359, 99418). (do not report g0317 for any time unit less than 15 minutes) | <1% | 825 | $3K |
| 99173 | <1% | 956 | $3K | |
| 31231 | <1% | 67 | $3K | |
| 01936 | <1% | 61 | $3K | |
| 17311 | <1% | 32 | $3K | |
| 99401 | <1% | 213 | $3K | |
| 74018 | <1% | 956 | $3K | |
| 95819 | <1% | 94 | $3K | |
| 82962 | <1% | 1,602 | $3K | |
| 69210 | <1% | 147 | $3K | |
| 94726 | <1% | 165 | $3K | |
| 72050 | <1% | 219 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 79 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 148 | $2K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,253 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,751 | $2K |
| 27096 | <1% | 17 | $2K | |
| 99402 | <1% | 46 | $2K | |
| 92551 | <1% | 290 | $2K | |
| 87210 | <1% | 822 | $2K | |
| 90961 | <1% | 95 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 98 | $2K |
| 90962 | <1% | 63 | $2K | |
| 90686 | <1% | 867 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 93 | $2K |
| 82948 | <1% | 2,178 | $2K | |
| 73610 | <1% | 94 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 678 | $1K |
| 97597 | <1% | 81 | $1K | |
| 72040 | <1% | 108 | $1K | |
| 11750 | <1% | 30 | $1K | |
| L1812 | Knee orthosis, elastic with joints, prefabricated, off-the-shelf | <1% | 39 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 935 | $1K |
| 97803 | <1% | 120 | $1K | |
| 73110 | <1% | 88 | $1K | |
| 82044 | <1% | 538 | $1K | |
| 72190 | <1% | 148 | $1K | |
| 31575 | <1% | 27 | $1K | |
| 93321 | <1% | 38 | $1K | |
| 99358 | Prolong nursin fac eval 15m | <1% | 128 | $1K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $1K |
| 43235 | <1% | 18 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 79 | $1K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 158 | $1K |
| 92550 | <1% | 217 | $1K | |
| 90661 | <1% | 46 | $1K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 298 | $1K |
| 90966 | <1% | 32 | $1K | |
| 99383 | <1% | 12 | $1K | |
| 99459 | <1% | 112 | $998.39 | |
| 97014 | <1% | 445 | $969.45 | |
| 90756 | <1% | 113 | $964.99 | |
| 64491 | <1% | 24 | $945.48 | |
| 11056 | <1% | 109 | $936.48 | |
| 20526 | <1% | 38 | $932.51 | |
| L2795 | Addition to lower extremity orthosis, knee control, full kneecap | <1% | 39 | $890.94 |
| 92555 | <1% | 99 | $874.31 | |
| 92556 | <1% | 98 | $871.77 | |
| 3008F | <1% | 3,391 | $854.00 | |
| 52000 | <1% | 17 | $826.06 | |
| 64484 | <1% | 15 | $823.90 | |
| 97164 | <1% | 52 | $817.63 | |
| 64633 | <1% | 18 | $784.37 | |
| 73130 | <1% | 73 | $760.39 | |
| 96161 | <1% | 109 | $739.71 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 49 | $734.39 |
| 73560 | <1% | 72 | $708.94 | |
| 97012 | <1% | 172 | $689.73 | |
| 99305 | <1% | 87 | $656.57 | |
| 97162 | <1% | 13 | $619.93 | |
| 93320 | <1% | 19 | $592.56 | |
| 99460 | <1% | 14 | $591.94 | |
| 99318 | <1% | 15 | $558.50 | |
| 94375 | <1% | 27 | $550.08 | |
| 73030 | <1% | 65 | $548.47 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $540.12 |
| 72131 | <1% | 29 | $538.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 766 | $516.95 |
| 93922 | <1% | 49 | $502.62 | |
| 76642 | <1% | 35 | $495.46 | |
| 73100 | <1% | 28 | $483.47 | |
| 95024 | <1% | 38 | $459.90 | |
| 99177 | <1% | 96 | $456.63 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 33 | $444.88 |
| 76536 | <1% | 15 | $427.63 | |
| 99487 | Ccm add 20min | <1% | 356 | $373.16 |
| 99152 | <1% | 31 | $361.61 | |
| G0318 | Prolonged home or residence evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99345, 99350 for home or residence evaluation and management services). (do not report g0318 on the same date of service as other prolonged services for evaluation and management 99358, 99359, 99417). (do not report g0318 for any time unit less than 15 minutes) | <1% | 55 | $318.18 |
| 77002 | <1% | 18 | $307.95 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 659 | $307.88 |
| 99347 | <1% | 22 | $305.94 | |
| 64634 | <1% | 18 | $294.90 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $289.55 |
| 96160 | <1% | 64 | $288.74 | |
| 70220 | <1% | 14 | $287.53 | |
| 17000 | <1% | 30 | $274.29 | |
| 90461 | <1% | 291 | $274.00 | |
| 93298 | <1% | 66 | $273.99 | |
| 90670 | <1% | 326 | $248.36 | |
| 11900 | <1% | 13 | $243.63 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 21 | $241.33 |
| 1160F | <1% | 228 | $220.00 | |
| 1159F | <1% | 375 | $220.00 | |
| 81001 | <1% | 118 | $204.06 | |
| 92504 | <1% | 14 | $199.42 | |
| 99024 | <1% | 3,799 | $187.02 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $148.31 |
| 90688 | <1% | 47 | $144.53 | |
| 71250 | <1% | 14 | $130.00 | |
| 11720 | <1% | 48 | $125.80 | |
| 0503F | <1% | 88 | $120.06 | |
| 93288 | <1% | 29 | $102.15 | |
| 90656 | <1% | 17 | $101.78 | |
| 0502F | <1% | 4,905 | $80.00 | |
| G0008 | Administration of influenza virus vaccine | <1% | 91 | $76.21 |
| 99489 | Ccm add 20min | <1% | 96 | $69.73 |
| 74019 | <1% | 13 | $42.80 | |
| 85018 | <1% | 41 | $39.33 | |
| 0501F | <1% | 283 | $30.00 | |
| 99453 | <1% | 19 | $29.10 | |
| 82270 | <1% | 19 | $22.47 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 38 | $20.65 |
| 1111F | <1% | 14 | $20.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 21 | $14.91 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 24 | $12.10 |
| G9500 | Radiation exposure indices documented in final report for procedure using fluoroscopy | <1% | 14,777 | $0.09 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | <1% | 16,078 | $0.08 |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility | <1% | 16,023 | $0.08 |
| A4208 | Syringe with needle, sterile 3 cc, each | <1% | 18 | $0.04 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 951 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 231 | $0.00 |
| 90633 | 0% | 27 | $0.00 | |
| 3342F | 0% | 23 | $0.00 | |
| 99188 | 0% | 26 | $0.00 | |
| G9340 | Final report documented that dicom format image data available to non-affiliated external healthcare facilities or entities on a secure, media free, reciprocally searchable basis with patient authorization for at least a 12-month period after the study | 0% | 38 | $0.00 |
| 90621 | 0% | 17 | $0.00 | |
| G2058 | Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). | 0% | 247 | $0.00 |
| 1036F | 0% | 162 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 56 | $0.00 |
| 4037F | 0% | 114 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 368 | $0.00 |
| 97010 | 0% | 219 | $0.00 | |
| G9637 | Final reports with documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique) | 0% | 238 | $0.00 |
| 90698 | 0% | 83 | $0.00 | |
| 1000F | 0% | 20 | $0.00 | |
| 7025F | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCALENDINE, CHAD (PRESIDENT)